TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01342458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexible footwear
Description: The patients of the Intervention Group (IG) will be use over 6 month a flexible and non-heeled footwear (Moleca; Calçados Beira Rio S.A., Novo Hamburgo, Rio Grande do Sul, Brazil) is a women's flexible flat walking shoe, without heels, with an anti-slip rubber sole, 5-mm thin, with a 3 mm internal wedge of ethylene vinyl acetate, made out of dubbed canvas. It had a mean weight of 172 ± 19.6 g, ranging from 142 to 193 g depending upon the size.
Study: NCT02946840

Intervention type: DEVICE
Intervention: FNA with 25 G Beacon needle
Study: NCT02659787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2mg Buprenorphine
Description: Sublingual buprenorphine tablets (0.2mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01936701

Intervention type: PROCEDURE
Group type: OTHER
Intervention: bilateral cataract surgery
Description: same-day bilateral cataract surgery with implantation of intraocular lens

Intervention type: PROCEDURE
Group type: OTHER
Intervention: bilateral cataract surgery
Description: same-day bilateral cataract surgery with implantation of intraocular lens
Study: NCT01036308

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pure fibre-product
Description: The subjects consumed 25 g pure fibre-product per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pure fibre-product
Description: The subjects consumed 25 g pure fibre-product per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pure fibre-product
Description: The subjects consumed 25 g pure fibre-product per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
Study: NCT00387998

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AHRQ staying healthy booklet
Description: educational booklet about prevention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk primer
Description: Know your chances booklet
Study: NCT03752671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of INTRASPINE device
Description: The surgical technique for excision of the disc hernia is the surgeon's usual technique: patient positioning (lying on his/her back or front or in the knee to chest position) the approach to the lumbar disc hernia (interlaminar or interspinous), closure and drainage of the operation site are performed by the surgeon's usual practice.~IntraSPINE® is positioned once surgery for the disc hernia has been performed. The implant bed is prepared with the assistance of the distractor provided. The choice of implant size is made after positioning the trial device corresponding to the anatomical bed. Once the size has been established the corresponding implant is placed in a cup of physiological saline prior to implantation. Implantation is performed using the appropriate implant holder.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Discectomy
Description: The surgical technique for excision of the disc hernia is the surgeon's usual technique: patient positioning (lying prone or supine or in the knee to chest position). The approach to the lumbar disc hernia (interlaminar or interspinous), closure and drainage of the operation site are performed using the surgeon's normal practice.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discectomy
Description: The surgical technique for excision of the disc hernia is the surgeon's usual technique: patient positioning (lying prone or supine or in the knee to chest position). The approach to the lumbar disc hernia (interlaminar or interspinous), closure and drainage of the operation site are performed using the surgeon's normal practice.
Study: NCT01615081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The acute effect of malt extract versus sucrose on the response of glucose and insulin, subjective appetite sensations and ad libitum energy intake
Description: 2-arm crossover study for investigation of the effect of malt extract vs. sucrose on glucose, insulin, subjective appetite sensations and ad libitum energy intake.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The acute effect of malt extract versus sucrose on the response of glucose and insulin, subjective appetite sensations and ad libitum energy intake
Description: 2-arm crossover study for investigation of the effect of malt extract vs. sucrose on glucose, insulin, subjective appetite sensations and ad libitum energy intake.
Study: NCT02099500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: Liposuction using aspiration syringe and tumescent local anesthesia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stem Cell Injection
Description: Stem cell implantation will be performed using intramuscular injection into the affected ischemic site of interest
Study: NCT01474278

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5028442
Description: Single dose
Study: NCT03376594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benjakul Extract
Description: 30 patients taking Benjakul Extract dosage 100 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loratadine
Description: 30 patients taking Loratadine dosage 10 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.
Study: NCT02920164

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auricular acupuncture
Description: Auricular acupuncture with indwelling permanent needles

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupuncture
Description: Placebo acupuncture with placebo needles
Study: NCT02946164

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stick To It
Description: The intervention is a prize system linked to points earned through online and real-world activities designed to incentivize young MSM to test for HIV and STIs every three months. Participants receive points for pre-determined activities, such as: answering online quizzes, inviting friends to participate, and getting tested for HIV/STIs. Points are redeemable in person at two AIDS Healthcare Foundation Men's Wellness Centers, where participants will be able to exchange their points for gumballs from a gumball machine; different color combinations of gumballs correspond to prizes of different values. Participants are reminded to get tested regularly via SMS messages; in addition, they can check when their next test is due by checking their testing timer on the stick2it.org website.
Study: NCT02780778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Targeted therapy Apatinib：500 mg，po，qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: chemotherapy Docetaxel：60mg/m²，vein input 1hour，every 3w
Study: NCT02737306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140
Description: PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in parenteral solution.
Study: NCT02736500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 28 GBq 177Lu-DOTATATE
Description: Patients without risk factors (particularly long standing and poorly controlled diabetes and hypertension) for late renal toxicity will be administered with 5 cycles of 5.5 GBq (150 mCi) each, up to the total cumulative activity of 28 GBq (750 mCi) of 177Lu-DOTATATE.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 22 GBq 177Lu-DOTATATE
Description: Patients with risk factors for late renal toxicity will be administered with 6 cycles of 3.7 GBq (100 mCi) each, up to the total cumulative activity of 22 GBq (600 mCi)177Lu-DOTATATE
Study: NCT05253560

Intervention type: DIAGNOSTIC_TEST
Intervention: The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.
Description: Tests to help identify prodromal PD in a cohort of carriers of Gaucher disease

Intervention type: DIAGNOSTIC_TEST
Intervention: The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.
Description: Tests to help identify prodromal PD in a cohort of carriers of Gaucher disease

Intervention type: DIAGNOSTIC_TEST
Intervention: The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.
Description: Tests to help identify prodromal PD in a cohort of carriers of Gaucher disease
Study: NCT05159635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Living programme and wearable technical aids
Description: attend 6 weeks active living programme and apply wearable technical aids for 8 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wearable technical aids
Description: apply wearable technical aids for 8 weeks.
Study: NCT01036308

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: reference fibre
Description: The subjects consumed 25 g reference fibre (citrus fibre: Herbacel AQ Plus; Herbafood Ingredients) per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: reference fibre
Description: The subjects consumed 25 g reference fibre (citrus fibre: Herbacel AQ Plus; Herbafood Ingredients) per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: reference fibre
Description: The subjects consumed 25 g reference fibre (citrus fibre: Herbacel AQ Plus; Herbafood Ingredients) per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
Study: NCT00642902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept will be administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 32 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept will be administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 32 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept will be administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to atacicept
Description: Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
Study: NCT03590600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: Powder and solvent for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: Powder and solvent for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: Powder and solvent for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: Powder and solvent for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: Powder and solvent for oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo: powder and solvent for oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo: powder and solvent for oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo: powder and solvent for oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo: powder and solvent for oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo: powder and solvent for oral suspension
Study: NCT00901888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin infusion
Description: Infusion of up to 10picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apelin infusion
Description: Infusion of up to 10picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside infusion
Description: Infusion of up to 150-600picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium nitroprusside infusion
Description: Infusion of up to 150-600picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
Study: NCT04034108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical intervention combined with weight-supported ambulation training
Description: Surgeries were performed between 12 hours to 30 days after trauma. Internal fixation was implemented once instability of the injured spinal column was confirmed by radiology and exploration during operation. At 15 days after surgery, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers. The training program was named Kunming Locomotor Training Program (KLTP)formulated by actively walking for a duration of 6 hours per day, 6 days per week for a minimum of 6 months.
Study: NCT03156933

Intervention type: OTHER
Intervention: Assessment of splicing variants
Description: This is a biological study with primary samples without any intervention on patients.
Study: NCT00846638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: Diagnostic assessment followed by a single session Brief Intervention with 3, 6, and 12 month follow-up

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic assessment
Description: Single session diagnostic assessment with 12 month followup
Study: NCT02913066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S-1 concurrent radiotherapy
Description: Radiotherapy 60\~66 Gray/28\~33 times (50.4\~60 Gray /28\~33 planning target volume times, 60\~66 Gray/28\~33 Gross tumor volume of primary tumor), synchronous chemotherapy S-1 70 mg/m2 5 to 1 per week, to the end of radiotherapy. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1, 70 mg/m2, 1\~ 14 days, 21 days for a cycle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: S-1 plus Cisplatin concurrent radiotherapy
Description: Radiotherapy 60\~66 Gray/28\~33 times (50.4\~60 Gray /28\~30 planning target volume times, Gross tumor volume of primary tumor60\~66 Gray/28\~33), synchronous chemotherapy S-1 70 mg/m2 1\~ 14 days and 29 to 42 days, plus cisplatin 25mg/m2 1\~ 4 days and 29 to 33 days. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1 70 mg/m2 1\~ 14 days, plus cisplatin 25mg/m2 1\~ 4 days, 21 days for a cycle.
Study: NCT05197361

Intervention type: DIAGNOSTIC_TEST
Intervention: Invasive coronary physiology
Description: Estimation of guide-wire coronary physiology parameters
Study: NCT02615236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: perineal ultrasound
Description: transvaginal probe will be used to scan the perineum immediately after vaginal delivery in primiparous women

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical diagnosis
Description: diagnosis of OASIS clinically
Study: NCT03076541

Intervention type: DEVICE
Intervention: standard 24-h ambulatory polysomnography
Description: A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
Study: NCT00915135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon and Placebo (25 possible combinations total)
Description: Randomized sequence over two consecutive nights for a total of five treatment periods to include the following:~Ramelteon 4 mg, tablets, orally over two nights~Ramelteon 8 mg, tablets, orally over two nights~Ramelteon 16 mg, tablets, orally over two nights~Ramelteon 32 mg, tablets, orally over two nights~Ramelteon placebo-matching tablets, orally over two nights
Study: NCT01438125

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MF-4181
Description: Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgical wound closure
Description: Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
Study: NCT03516643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Myocardial Revascularization
Description: extracorporeal shockwave in ischemic area evaluated by SPECT
Study: NCT02207725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03408275

Intervention type: OTHER
Intervention: None - observational
Description: None - observational
Study: NCT01718093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: up to 50 mg twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: up to 1000 mg twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin + Metformin
Description: up to 50/1000 mg twice a day
Study: NCT01568268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: palonosetron 0.075 mg intravenous injection over 10 seconds when nausea with NRS \>= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo control group
Description: placebo intravenous injection over 10 seconds when nausea with NRS \>= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
Study: NCT01578863

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention program for obese children
Description: The program includes physical activity, nutrition intervention and behavioral treatment and lasts for 6 months. The aim of the program is to promote weight loss and physical activity and to promote future healthy lifestyle.
Study: NCT03484455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypothermic machine perfusion
Description: Organ Recovery Systems LifePort® Liver Transporter (LLT) System and Vasosol® Machine Perfusion Solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Static cold storage
Description: Static cold storage (standard of care)
Study: NCT00336141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suberoylanilide hydroxamic acid
Description: 400 mg QD (every day) for five days, followed by 9 days of no vorinostat
Study: NCT03725839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F&P Interface
Description: F\&P Interface to be used for OSA therapy
Study: NCT01520402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Enrolled subjects on a fixed vitamin K diet followed a standard warfarin dosing algorithm with daily point-of-care INR checks to goal INR ≥ 2 for two consecutive days, then to baseline INR≤1.2 off warfarin. Genotyping for common and rare polymorphisms in CYP2C9, VKORC1, and CYP4F2 performed at study entry and unblinded at completion. Plasma Vitamin K and S-warfarin levels are obtained at goal INR ≥ 2 and study exit (INR ≤1.2 off warfarin).
Study: NCT02878928

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: IDgenetix Neuropsychiatric Test Panel
Description: The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
Study: NCT02819102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353 and probes
Study: NCT02600884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families Talking Together Plus (FTT+HPV)
Description: Intervention parents will attend a 1-hour intervention session and receive program materials to use with youth at home and 2 booster phone calls post intervention. Content of the experimental intervention includes parent child sexual health communication and HPV vaccination navigation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief motivational interviewing (BMI)
Description: Control parents will attend a 1-hour intervention session and receive program materials to use with youth at home and 2 booster phone calls post intervention. Content of the control intervention includes obesity prevention strategies using motivational interviewing.
Study: NCT03522948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief intervention with text messaging to reduce sexual risk and heavy drinking among MSM
Description: Combines a brief in-person motivational intervention with personalized cognitive counseling elements and 4 weeks of personalized text messaging to support goals related to sexual risk behavior and alcohol use
Study: NCT03713138

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flaxseed powder
Description: Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.